Head-to-head
CoreAge Rx vs SkinnyRx
CoreAge Rx and SkinnyRx both offer GLP-1 telehealth, but they make different trade-offs on speed to first dose, flat pricing, access and molecule choice. Here they are side-by-side on the Rx-Readiness Score — our readiness rubric.
CoreAge Rx
Higher scoreRanked #1 · Grade A
Best for: Working moms who want a decision, not a research project — flat pricing, both semaglutide and tirzepatide, and no scheduled video visit to book around work and pickup.
Visit CoreAge RxSkinnyRx
Ranked #101 · Grade C
Best for: Working moms willing to verify SkinnyRx's compounding and ingredient claims for themselves rather than take its labels or marketing at face value — the FDA found the site misrepresents who actually compounds these products and implies an FDA-approved status they don't have. Read the FDA's letter before you weigh in the tablet option or the flat pricing.
Visit SkinnyRxThe verdict
CoreAge Rx edges out SkinnyRx on the Rx-Readiness Score, 95 to 57 (A vs C). Working moms who want a decision, not a research project — flat pricing, both semaglutide and tirzepatide, and no scheduled video visit to book around work and pickup.
SkinnyRx is still a genuine option — a flat $199/mo semaglutide, $299/mo tirzepatide, with an option most of this batch skips: a sublingual tablet instead of a weekly shot, plus no video visit required — but the FDA issued its parent entity, Lean Rx, Inc., a warning letter on 02/20/2026 (ref. 717989) for mislabeling itself as the compounder on its own product images and for marketing language implying its compounded products share FDA-approved status with Mounjaro and Zepbound, which they don't. Confirmed directly on FDA.gov; SkinnyRx's own site never mentions it. Weigh the six readiness factors below against your own priorities.
Side-by-side on the six factors
Both providers scored on the same readiness rubric — the higher side on each factor is marked. See the methodology.
Price, access & features
| Detail | CoreAge Rx | SkinnyRx |
|---|---|---|
| Rx-Readiness Score | 95/100 · A | 57/100 · C |
| Overall rank | #1 | #101 |
| Semaglutide | $99/mo | $199/mo |
| Tirzepatide | $149/mo | $299/mo |
| Coverage | All 50 states | Not disclosed on the public site we reviewed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
CoreAge Rx
Ranked #1 · Grade A
What we like
- Flat monthly price that stays put through titration — no dose-scaling surprise on your busiest month
- Both compounded semaglutide and tirzepatide on one plan, so you're not re-signing to switch
- Async, no-video intake and all-50-states coverage — start it during a lunch break
The caveats
- Not the rock-bottom sticker price — a couple of teaser tiers elsewhere start lower
- Compounded only — no FDA-approved brand option
- General metabolic program, not a boutique concierge service
SkinnyRx
Ranked #101 · Grade C
What we like
- Offers sublingual tablets as a genuine alternative to injections for both molecules
- Flat pricing regardless of dose
- No video visit mentioned in its process description
The caveats
- No state list published anywhere on the public site
- Pricing only surfaces in compiled app data, not a plain page read
- No stated time-to-first-dose window
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Rx-Readiness Score. Pricing, states and verification reflect each provider's public disclosures at last review; the Rx-Readiness Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.
More head-to-heads
Keep comparing CoreAge Rx and SkinnyRx against other providers on our shortlist.
Or browse the full comparison hub.